Pharmafile Logo

Gower Publishing

- PMLiVE

Janssen scores another expansion for new Darzalex combination in the US

Myeloma med approved in combination with Amgen's Kyprolis

- PMLiVE

Novartis wins FDA approval for relapsing MS drug Kesimpta

Swiss pharma company is expecting EU approval for treatment next year

- PMLiVE

Pifzer, BioNTech eye October approval for mRNA-based COVID-19 vaccine

Companies share additional phase 1 safety and tolerability data

- PMLiVE

Trust – years to build, seconds to break and forever to repair

Can pharma maintain the trust built during the coronavirus?

Using Health IT to Improve the Healthcare System

Scott Arrol, Chief Executive Officer at New Zealand Health IT, discusses the roles of interoperability, connected health, and digital identity in enabling a healthier population. We also explore how NZHIT and...

Impetus Digital

- PMLiVE

NICE recommends Roche’s Polivy for B-cell lymphoma

Cost-effectiveness agency approves drug following initial rejection earlier this year

- PMLiVE

US payments for COVID-19 vaccines tied to specific timing milestones

Full pay-out is dependent on achieving regulatory approval by certain dates

- PMLiVE

Roche, Regeneron partner on COVID-19 antibody cocktail

Collaboration agreement will bolster global development and manufacturing capabilities

- PMLiVE

J&J inks $6.5bn all-cash deal to acquire Momenta

Acquisition sees J&J gain access to portfolio of autoimmune disease treatments

Lucid Group reaches the finals of the PM360 2020 Trailblazer Initiative Awards

Lucid Group has been named as a finalist in the PM360 2020 Trailblazer Initiative Awards in the HCP Education category, for the program LiBRA 2019: Looking beyond the joint in...

Lucid Group Communications Limited

- PMLiVE

GSK doses first patients in phase 3 meningitis vaccine trial

Clinical programme will test five-in-one vaccine candidate

- PMLiVE

Britain ramps up COVID-19 testing to track spread of infections

Regular testing will increase from 28,000 people per fortnight to 150,000 by October

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links